Sign In
Buy PCRX
$22.32
+0.0700 (+0.315%)
At Close: Jun 03, 2026
Pacira Announces Publication of Pivotal Study of EXPAREL as a Sciatic Nerve Block in the Popliteal Fossa for Patients After Bunionectomy
08:36am, Thursday, 15'th Feb 2024
– Findings demonstrate significant reduction in pain and opioid consumption through 96 hours versus active comparator –
Pacira BioSciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
08:00am, Wednesday, 03'rd Jan 2024
TAMPA, Fla., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the 42nd Annual J.P. Morgan Healthcare Conference at 8:15 AM PT (11:15 AM
Pacira (PCRX) Q3 Earnings and Revenues Miss, '23 View Updated
02:17pm, Thursday, 02'nd Nov 2023
Pacira (PCRX) announces weaker-than-expected third-quarter 2023 results. The company streamlines its 2023 guidance for net Exparel sales.
Pacira to Report Third Quarter 2023 Financial Results on Thursday November 2, 2023
08:00am, Thursday, 26'th Oct 2023
TAMPA, Fla., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its third quarter financial results before the open of the U.S. markets on Thu
Pacira BioSciences Announces Fireside Chat at the H.C. Wainwright 25th Annual Global Investment Conference
08:00am, Wednesday, 06'th Sep 2023
TAMPA, Fla., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced its participation in an analyst-led fireside chat at the H.C. Wainwright 25th Annual Global Inve
Pacira (PCRX) Q2 Earnings and Sales Miss, '23 View Updated
02:12pm, Wednesday, 02'nd Aug 2023
Pacira (PCRX) announces weaker-than-expected second-quarter 2023 results. The company updates its 2023 financial guidance.
Pacira BioSciences, Inc. (PCRX) Q2 2023 Earnings Call Transcript
12:36pm, Wednesday, 02'nd Aug 2023
Pacira BioSciences, Inc. (NASDAQ:PCRX ) Q2 2023 Earnings Conference Call August 2, 2023 8:30 AM ET Company Participants Susan Mesco - Head of IR David Stack - Chairman & CEO Charles Reinhart - CFO Con
Why Is Pacira (PCRX) Down 11.8% Since Last Earnings Report?
12:39pm, Friday, 02'nd Jun 2023
Pacira (PCRX) reported earnings 30 days ago. What's next for the stock?
Here's Why You Should Add Pacira (PCRX) Stock to Your Portfolio
09:55am, Monday, 15'th May 2023
Pacira (PCRX) is witnessing strong growth on the back of its lead product, Exparel. Potential label expansion is set to boost sales in future quarters.
Pacira BioSciences to Participate in Fireside Chat at the 2023 RBC Capital Markets Global Healthcare Conference
08:00am, Tuesday, 09'th May 2023
TAMPA, Fla., May 09, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the 2023 RBC Capital Markets Global He
Pacira (PCRX) Q1 Earnings Miss Estimates, Revenues Beat
04:42pm, Wednesday, 03'rd May 2023
Pacira (PCRX) misses on Q1 earnings but beats on revenues, even though volume growth of Exparel is offset by lower selling prices.
Biotech/Drug Stocks' Q1 Earnings Due May 3: UTHR, PCRX & More
02:32pm, Tuesday, 02'nd May 2023
Let us take a look at what's in store for biotech/drug stocks UTHR, PCRX, CORT, AMRN and IONS, which are scheduled to report on May 3.
Pacira to Report First Quarter 2023 Financial Results on Wednesday May 3, 2023
08:00am, Wednesday, 26'th Apr 2023
TAMPA, Fla., April 26, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its first quarter financial results before the open of the U.S. markets on We
Why Is Pacira (PCRX) Down 6% Since Last Earnings Report?
12:56pm, Thursday, 30'th Mar 2023
Pacira (PCRX) reported earnings 30 days ago. What's next for the stock?
Pacira's (PCRX) sNDA for Exparel Accepted for FDA Review
09:54am, Thursday, 30'th Mar 2023
The FDA accepts Pacira's (PCRX) sNDA filing, which seeks to expand the label of its pain drug Exparel to include both sciatic and femoral nerve blocks. A final decision is expected by November 2023.
